AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03263650
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
Trial: NCT03263650
Drug: Prednisone 5Mg
RxNorm normalized name: PREDNISONE 5MG TAB
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
Trial: NCT04582448
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
Trial: NCT03263650
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
Trial: NCT04285281
Drug: Gabapentin oral capsules
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule pharmaceutical treatment.
Trial: NCT02742779
Drug: GDC-0310
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
Trial: NCT00035165
Drug: epothilone b
RxNorm normalized name: Epothilone B
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
Trial: NCT04447833
Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
Trial: NCT00002911
Drug: marimastat
RxNorm normalized name: Marimastat
DrugBank: Marimastat (DB00786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03436654
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240mg daily orally
Trial: NCT03436654
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000mg daily orally
Trial: NCT03436654
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID orally
Trial: NCT02046733
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
Trial: NCT02046733
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
Trial: NCT00815269
Drug: Halothane
RxNorm normalized name: Halothane
DrugBank: Halothane (DB01159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
Trial: NCT00815269
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Trial: NCT00815269
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Trial: NCT00815269
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Trial: NCT00815269
Drug: Enflurane
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Trial: NCT02393196
Drug: hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before spinal anesthesia
Trial: NCT02393196
Drug: hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Just after spinal anesthesia
Trial: NCT02934828
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
Trial: NCT00006324
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02934828
Drug: postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
Trial: NCT02129829
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil 245 mg once daily
Trial: NCT03824171
Drug: Raloxifene 60mg/Cholecalciferol 800IU
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60mg/Cholecalciferol 800IU tablet
Trial: NCT03824171
Drug: AD-102
RxNorm normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
Trial: NCT06185127
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
Trial: NCT06185127
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
Trial: NCT06185127
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
Trial: NCT00271804
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00289367
Drug: Triiodothyronine
RxNorm normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
Trial: NCT00289367
Drug: triiodothyronine
RxNorm normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
Trial: NCT01199731
Drug: GSK2248761 200 mg once daily
RxNorm normalized name: eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 100mg capsules OAD
Trial: NCT01199731
Drug: Etravirine
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 100mg tablets twice daily
Trial: NCT00895583
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
Trial: NCT00895583
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
Trial: NCT00895583
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
Trial: NCT00756847
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous injection dosed once every three weeks
Trial: NCT00756847
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection dosed once every three weeks
Trial: NCT04387110
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Receiving either 1infusion (600mg) or 2 infusions (300mg).
Trial: NCT04101136
Drug: Atorvastatin - placebo controlled clinical trial
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
Trial: NCT00948402
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1250 mg three times daily
Trial: NCT00948402
Drug: oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
Trial: NCT01657487
Drug: Fluticasone/Salmeterol high dose
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00097019
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02789111
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alviimopan 12 mg twice daily up to 15 doses
Trial: NCT01252628
Drug: PX-866 (SCCHN)
RxNorm normalized name: PX-102
DrugBank: PX-102 (DB15416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Trial: NCT01252628
Drug: Cetuximab (SCCHN)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
Trial: NCT01252628
Drug: PX-866 (CRC)
RxNorm normalized name: cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Trial: NCT01252628
Drug: Cetuximab (CRC)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
Trial: NCT01488578
Drug: Tolterodine tartrate
RxNorm normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
Trial: NCT00548288
Drug: pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05359432
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Receiving allocated drug dosage as per clinical needs
Trial: NCT05359432
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Receiving allocated drug dosage as per clinical needs
Trial: NCT01577095
Drug: TZD
RxNorm normalized name: Thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg single dose
Trial: NCT01642407
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Trial: NCT01663168
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02545595
Drug: Sugammadex 1 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02545595
Drug: Sugammadex 2 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02545595
Drug: Sugammadex 4 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04177953
Drug: Carboplatin AUC 5
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy iv
Trial: NCT00034515
Drug: denufosol tetrasodium (INS37217) Inhalation Solution
DrugBank: Denufosol (DB04983)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790075
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was \>30 minutes.
Trial: NCT02033876
Drug: Ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00366379
Drug: GK Activator (2)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-200mg po bid for 20 weeks
Trial: NCT01015911
Drug: SGN-75
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
Trial: NCT01701778
Drug: Caudal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline
Trial: NCT01701778
Drug: Intravenous Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg
Trial: NCT01701778
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction and maintain anaesthesia
Trial: NCT03793075
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
Trial: NCT03793075
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol 17 mcg /kg/min
Trial: NCT02431403
Drug: ESHAP-Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
Trial: NCT04177953
Drug: Cisplatin 75 mg/m2
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy iv
Trial: NCT04177953
Drug: Pemetrexed 500 mg/m2
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: chemotherapy iv
Trial: NCT04409002
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
Trial: NCT04409002
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
Trial: NCT03532477
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription metaprolol medication
Trial: NCT00125567
Drug: Stalevo (levodopa/carbidopa/entacapone)
RxNorm normalized name: Stalevo
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 50-150 mg levodopa four times daily, for up to 2 years
Trial: NCT00030173
Drug: Epothilone D (KOS-862)
RxNorm normalized name: D
DrugBank: Epothilone D (DB01873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00373659
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02140073
Drug: omeprazole+domperidone SR
RxNorm normalized name: Domperidone
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
Trial: NCT02140073
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg in the morning
Trial: NCT02285114
Drug: F/TAF
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: F/TAF tablets administered orally once daily
Trial: NCT02285114
Drug: 3rd ARV agent
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).
Trial: NCT02285114
Drug: Boosted PIs
RxNorm normalized name: PI-103
DrugBank: PI-103 (DB17046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.
Trial: NCT03101423
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
Trial: NCT03101423
Drug: Donor Regulatory T-Lymphocytes
RxNorm normalized name: rabbit anti-human T-lymphocyte globulin
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
Trial: NCT00618397
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
Trial: NCT02340156
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
Trial: NCT00319449
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin